Alanyl-glutamine consumption modifies the suppressive effect of L-asparaginase on lymphocyte populations in mice

Journal of Nutrition

Volumn 138, Issue 2, 2008, Pages 338-343

  Bunpo, Piyawan ^a   Murray, Betty ^a   Cundiff, Judy ^a   Brizius, Emma ^a   Aldrich, Carla J ^a   Anthony, Tracy G ^a  

^a Indiana University School of Medicine Evansville   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLGLUTAMINE; ASPARAGINASE; CD11B ANTIGEN; CD45 ANTIGEN; IMMUNOGLOBULIN M; INITIATION FACTOR 2;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DEPLETION; CELLULAR IMMUNITY; CONTROLLED STUDY; DEPLETION; DIET SUPPLEMENTATION; FEMALE; FLOW CYTOMETRY; IMMUNE SYSTEM; LYMPHOCYTE SUBPOPULATION; MALE; METABOLIC STRESS; MOUSE; NONHUMAN; PHOSPHORYLATION; PROTEIN INTAKE; PROTEIN MODIFICATION; SPLEEN; T LYMPHOCYTE; THYMUS;

ESCHERICHIA COLI; EUKARYOTA; MUS;

EID: 38949183325     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/138.2.338     Document Type: Article

References (43)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
2. Verma N, Kumar K, Kaur G, Anand S. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol. 2007;27:45-62.
3. Richards NG, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem. 2006;75:629-54.
4. Cairo MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335-9.
5. Pinheiro JP, Boos J. The best way to use asparaginase in childhood acute lymphatic leukaemia: still to be defined? Br J Haematol. 2004;125:117-27.
6. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1:241-54.
7. Friedman H. L-asparaginase induced immunosuppression: inhibition of bone marrow derived antibody precursor cells. Science. 1971;174:139-41.
8. Gieldanowski J. Studies on the immunosuppressive and anti-inflammatory action of L-asparaginase. Arch Immunol Ther Exp (Warsz). 1976;24:243-7.
9. Durden DL, Distasio JA. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and Vibrio succinogenes. Cancer Res. 1980;40:1125-9.
10. Durden DL, Distasio JA. Characterization of the effects of asparaginase from Escherichia coli and a glutaminase-free asparaginase from Vibrio succinogenes on specific ell-mediated cytotoxicity. Int J Cancer. 1981;27:59-65.
11. Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest. 1988;18:512-6.
12. Reinert RB, Oberle LM, Wek SA, Bunpo P, Wang XP, Mileva I, Goodwin LO, Aldrich CJ, Durden DL, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006;281:31222-33.
13. Kessel D, Bosmann H. Effects of L-Asparaginase on protein and glycoprotein synthesis. FEBS Lett. 1970;10:85-8.
14. Villa P, Corada M, Bartosek I. L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. Toxicol Lett. 1986;32:235-41.
15. Yaqoob P, Calder PC. Glutamine requirement of proliferating T lymphocytes. Nutrition. 1997;13:646-51.
16. O'Rourke AM, Rider CC. Glucose, glutamine and ketone body utilisation by resting and concanavalin A activated rat splenic lymphocytes. Biochim Biophys Acta. 1989;1010:342-5.
17. Eliasen MM, Brabec M, Gerner C, Pollheimer J, Auer H, Zellner M, Weingartmann G, Garo F, Roth E, et al. Reduced stress tolerance of glutamine-deprived human monocytic cells is associated with selective down-regulation of Hsp70 by decreased mRNA stability. J Mol Med. 2006;84:147-58.
18. Yeh CL, Hsu CS, Chen SC, Pai MH, Yeh SL. Effect of glutamine on cellular adhesion molecule expression and leukocyte transmigration in endothelial cells stimulated by plasma or peritoneal drain fluid from a surgical patient. Shock. 2006;25:236-40.
19. Kafkewitz D, Bendich A. Enzyme-induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr. 1983;37:1025-30.
20. Reeves P, Nielsen F, Fahey G Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet. J Nutr. 1993;123:1939-51.
21. Satoh J, Tsujikawa T, Fujiyama Y, Bamba T. Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. J Gastroenterol Hepatol. 2003;18:719-25.
22. Furst P, Albers S, Stehle P. Availability of glutamine supplied intravenously as alanylglutamine. Metabolism. 1989;38:67-72.
23. Rogero MM, Tirapegui J, Pedrosa RG, Castro IA, Pires IS. Effect of alanyl-glutamine supplementation on plasma and tissue glutamine concentrations in rats submitted to exhaustive exercise. Nutrition. 2006;22:564-71.
24. Reiff A, Zastrow M, Sun BC, Takei S, Mitsuhada H, Bernstein B, Durden DL. Treatment of collagen induced arthritis in DBA/1 mice with L-asparaginase. Clin Exp Rheumatol. 2001;19:639-46.
25. Distasio JA, Durden DL, Paul RD, Nadji M. Alteration in spleen lymphoid populations associated with specific amino acid depletion during L-asparaginase treatment. Cancer Res. 1982;42:252-8.
26. Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res. 1983;43:1602-5.
27. Narta UK, Kanwar SS, Azmi W. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol. 2007;61:208-21.
28. Broome JD. Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth. J Natl Cancer Inst. 1965;35:967-74.
29. Distasio JA, Niederman RA, Kafkewitz D, Goodman D. Purification and characterization of L-asparaginase with anti-lymphoma activity from Vibrio succinogenes. J Biol Chem. 1976;251:6929-33.
30. Coligan J, Kruisbeek A, Margulies D, Shevach E, Strober W, editors. Current protocols in immunology. Hoboken (NJ): John Wiley and Sons, Inc.; 2006.
31. Grigoryan RS, Panosyan EH, Seibel NL, Gaynon PS, Avramis IA, Avramis VI. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). In Vivo. 2004;18:107-12.
32. Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity. 2007;26:703-14.
33. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest. 2007;117:1049-57.
34. Story MD, Voehringer DW, Stephens LC, Meyn RE. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol. 1993;32:129-33.
35. Ueno T, Ohtawa K, Mitsui K, Kodera Y, Hiroto M, Matsushima A, Inada Y, Nishimura H. Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase. Leukemia. 1997;11:1858-61.
36. Eguiguren JM, Pui CH. Bone marrow necrosis and thrombotic complications in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1992;20:58-60.
37. Hanada T, Horigome Y, Inudoh M, Takita H. Osteonecrosis of vertebrae in a child with acute lymphocytic leukaemia during L-asparaginase therapy. Eur J Pediatr. 1989;149:162-3.
38. Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23:295-9.
39. Top PC, Tissing WJ, Kuiper JW, Pieters R, van Eijck CH. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer. 2005;44:95-7.
40. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346:425-34.
41. Ehlers MR. CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect. 2000;2:289-94.
42. Ugarova TP, Yakubenko VP. Recognition of fibrinogen by leukocyte integrins. Ann N Y Acad Sci. 2001;936:368-85.
43. Christensen JE, Andreasen SO, Christensen JP, Thomsen AR. CD11b expression as a marker to distinguish between recently activated effector CD8(+) T cells and memory cells. Int Immunol. 2001;13:593-600.